Loews Corp. (L) Falls 2.53% for January 06

Equities Staff |

One of the S&P 500’s big losers for Wednesday January 06 was Loews Corp. (L). The company’s stock fell 2.53% to $36.93 on volume of 974,024 shares.

The stock opened the day at 37.28 and traded between a low of $36.79 and a high of $37.41. The stock finished the day down $0.96 per share. Loews Corp. has an average daily volume of 1.64 million and a total float of 354.34 million shares. The 50-day SMA for Loews Corp. is $37.55 and its 200-day SMA is $38.39. The high for the stock over the last 52 weeks is $42.78 and the low is $34.40.

Loews Corp through its subsidiaries is engaged in commercial property & casualty insurance, operation of offshore oil & gas drilling rigs, production of natural gas and liquids, operation of interstate natural gas pipeline and operation of hotels.

Loews Corp. is centered in New York, NY, and has 17,510 employees. Today’s trading day leaves the company with a market cap of $13.09 billion. The company has a P/S ratio of n/a, P/B ratio of 0.7, and a 23.6.

For a complete fundamental analysis analysis of Loews Corp., check out Equities.com’s Stock Valuation Analysis report for L. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

CF0005, LLC dba Mesa-Marshall #1-2

MESA Resources, Inc. ("MESA") is sponsoring the development of the oil & gas well completion project "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development…


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…